|Bid||40.61 x 900|
|Ask||44.52 x 2200|
|Day's Range||41.55 - 43.19|
|52 Week Range||30.15 - 68.05|
|Beta (3Y Monthly)||4.13|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 25, 2019 - Mar 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||86.92|
David Kim’s Ghost Tree Capital is a health-care oriented hedge fund with a headquarter in New York. It was founded five years ago, back in 2013, by Ken Greenberg, Matt Diaz (Trader), Brian Kim (Senior Analysts), and of course David Kim. This large advisory firm provides portfolio management services for pooled investment vehicles and pension funds. David […]
The company reported boring third-quarter 2018 operating results, but followed up with important clinical updates in the first week of December.
NEW YORK, NY / ACCESSWIRE / December 10, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Global Blood Therapeutics , Inc. (GBT), a clinical-stage biopharmaceutical company. GBT is developing two therapies for the potential treatment of sickle cell disease, including its late-stage product candidate, voxelotor, as an oral, once-daily therapy. GBT plans to request a pre-NDA meeting for the first quarter of 2019 and intends to provide further details regarding its plans and timing for an NDA submission as well as additional specifics on the TCD confirmatory study following this meeting.
Global Blood Therapeutics, Inc. (GBT) (GBT), a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities, today announced the pricing of its underwritten public offering of its common stock for gross proceeds of approximately $150.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by GBT. In addition, GBT has granted the underwriters a 30-day option to purchase $22.5 million of additional shares of common stock. Cantor Fitzgerald & Co. is the sole book-running manager for the offering.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 6) Gritstone Oncology Inc (NASDAQ: GRTS ) Down In The Dumps ...
Analysts think there are three biotech stocks, in particular, that look like good picks right now: Stemline Therapeutics (STML), Global Blood Therapeutics (GBT), and Sesen Bio (SESN). The application has received priority review from the FDA and has a PDUFA date scheduled for February 21, 2019, which is when regulators will decide the drug's commercial fate. ELZONRIS has also been granted Breakthrough Therapy Designation and Orphan Drug Designation by the FDA. "Given the strength of the pivotal study data combined with the significant unmet clinical need for BPDCN patients, we believe there is a strong likelihood of approval by the PDUFA date," Ladenburg analyst Matthew Kaplan opined. "We believe SL-401 could generate $130 million U.S. revenues in the BPDCN indication at peak.
Global Blood Therapeutics, Inc. (GBT) (GBT), a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities, today announced an agreement to sell $150.0 million in shares of its common stock in a registered underwritten public offering. In addition, GBT has granted the underwriter a 30-day option to purchase up to $22.5 million in shares of its common stock. Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering. GBT intends to use the net proceeds from the offering and its existing capital resources to fund its clinical development of voxelotor for the treatment of sickle cell disease, including its ongoing clinical studies, as well as preparation for the potential commercial launch of voxelotor, if approved by the U.S. Food and Drug Administration, future clinical trials of voxelotor and other product candidates that GBT may elect to pursue, including inclacumab, its other research and development activities, and for working capital and general corporate purposes.
On CNBC's "Mad Money Lightning Round" , Jim Cramer said Booz Allen Hamilton Holding Corporation (NYSE: BAH ) is not a bad stock, but he likes Accenture Plc (NYSE: ACN ) a lot more. TE Connectivity ...
Jim Cramer tears through his responses to callers' questions, including one about the action in a book retailer's stock.
SOUTH SAN FRANCISCO, Calif., Dec. 04, 2018 -- Global Blood Therapeutics, Inc. (GBT or the Company) (NASDAQ: GBT) today announced that, on November 30, 2018, the compensation.
Global Blood Therapeutics (GBT) announces FDA nod for an accelerated approval pathway for voxelotor as a treatment for sickle cell disease. Stock rallies.
NEW YORK, NY / ACCESSWIRE / December 4, 2018 / U.S. markets closed up on Monday as the U.S. and China came to an agreement of a 90-day trade war truce at the G-20 meeting in Argentina. The Dow Jones Industrial ...
Global Blood announced Monday that the FDA has agreed to allow filing for its late-stage sickle cell disease, or SCD, candidate Voxelotor under an accelerated approval pathway. The company said it would submit a new drug application, or NDA, for the pipeline asset under the pathway. With Global Blood proposing that voxelotor reasonably reduces strokes in SCD patients, the FDA has accepted the transcranial doppler, or TCD, flow as the primary endpoint in a post-approval confirmatory study to demonstrate stroke risk reduction.
Shares of Global Blood Therapeutics Inc. shot up 40% Monday morning after the biotech company announced it had reached an agreement with the U.S. Food and Drug Administration to use an accelerated approval pathway for a potential sickle cell disease treatment. Voxelator, a once-a-day oral drug, works by increasing the binding of oxygen to hemoglobin, the molecule that carries oxygen in red blood cells. Global Blood thinks this would help prevent patients' red blood cells from clumping together, which would decrease the risk of stroke for those patients. Under the accelerated approval pathway, Global Blood will not need to conduct a clinical trial that proves voxelator reduces strokes until after the drug is approved, though it could be withdrawn after it hits the market if further studies show it doesn't provide a clear benefit. Shares of Global Blood have increased 11.6% in the year to date, while the S&P 500 has gained 4.3%.
Global Blood Therapeutics, Inc. (GBT) (GBT) today announced updated efficacy and safety results from Part A of its Phase 3 HOPE Study of voxelotor in patients age 12 and older with sickle cell disease (SCD). Preliminary results from 154 adolescents and adults with SCD treated with voxelotor for 24 weeks demonstrated rapid, robust and sustained improvements in hemoglobin levels and measures of hemolysis with a favorable safety and tolerability profile.
Global Blood Therapeutics, Inc. (GBT) (GBT) today announced that the U.S. Food and Drug Administration (FDA) has informed GBT through discussions and written correspondence that the agency agrees with the Company’s proposal relating to use of an accelerated approval pathway for voxelotor for the treatment of sickle cell disease (SCD). GBT plans to submit an NDA for voxelotor for the treatment of SCD under this pathway. GBT proposed that by raising hemoglobin, voxelotor is reasonably likely to reduce strokes in SCD patients.
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 02, 2018 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the company will host a conference call to.
Investors need to pay close attention to Global Blood Therapeutics (GBT) stock based on the movements in the options market lately.
NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.